BRIEF published on 10/12/2026 at 07:35, 25 days 21 hours ago Advicenne extends its cash reserves until 2028 Treasury Funding Sales Performance Nephrology Advicenna
BRIEF published on 10/12/2026 at 07:35, 25 days 21 hours ago Advicenne Secures Financial Stability with Extended Runway to 2028 Product Sales Bond Financing Advicenne Financial Runway Share Dilution Risks
PRESS RELEASE published on 10/12/2026 at 07:30, 25 days 21 hours ago Inside Information / Other news releases Advicenne extends financial visibility to 2028 thanks to bond financing and strong sales performance in neurology and nephrology Neurology Bond Financing Advicenne Nephrology Financial Visibility
BRIEF published on 09/28/2026 at 14:40, 1 month 8 days ago Advicenne publishes its monthly voting rights figures Share Capital Voting Rights AMF Share Issuance Advicenna
BRIEF published on 08/31/2026 at 07:05, 2 months 6 days ago Advicenne withdraws the application for registration of ADV7103 in the United States FDA Pharmaceutical Registration Advicenna Sibnayal
PRESS RELEASE published on 08/31/2026 at 07:00, 2 months 6 days ago Inside Information / Other news releases Advicenne voluntarily withdraws NDA for ADV7103 in the USA due to CMC-related work issues. Company hosting French webinar for shareholders. ADV7103 approved in EU, UK, KSA, UAE Pharmaceutical Webinar Advicenne ADV7103 NDA Withdrawal
BRIEF published on 07/16/2026 at 18:40, 3 months 21 days ago Advicenne's Revenue Surge in First Half of 2026 Revenue Growth Advicenne Sibnayal® Likozam® Pharmaceutical Sales
PRESS RELEASE published on 07/16/2026 at 18:35, 3 months 21 days ago Inside Information / Other news releases Advicenne reports significant revenue growth in first half of 2026 driven by Sibnayal® and Likozam® reimbursement in France, ending negative impact of early access rebates. Sales of Sibnayal® and Likozam® increased in volume Revenue Growth France Advicenne Sibnayal® Likozam®
BRIEF published on 07/01/2026 at 17:50, 4 months 5 days ago Unlimited renewal of the marketing authorization for Sibnayal® by Advicenne in the United Kingdom United Kingdom Advicenna Sibnayal Rare Kidney Diseases Marketing Authorization Renewal
BRIEF published on 06/22/2026 at 19:12, 4 months 14 days ago Advicenne Secures Financing to Q2 2027 with New Bond Issue Strategic Development Bond Financing FDA Registration Advicenne Rare Kidney Diseases
Published on 11/06/2026 at 22:15, 7 hours 4 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 16 hours 19 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 16 hours 49 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 16 hours 49 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 20:15, 9 hours 4 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 10 hours 4 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 10 hours 19 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 10 hours 47 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 18:00, 11 hours 19 minutes ago ARVERNE GROUP: Number shares and voting rights
Published on 11/06/2026 at 18:00, 11 hours 19 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 11/06/2026 at 17:54, 11 hours 25 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 11 hours 44 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
